Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00178256
Status:
COMPLETED
Last Update Posted:
2015-08-21
First Post:
2005-09-12
Brief Title:
Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable Stage III Or Unresectable Lung Cancer
Sponsor:
University of Rochester
Organization:
University of Rochester
Study Overview
Official Title:
A Phase III Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable Stage III Or Unresectable Stage III Lung Cancers
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A treatment study is being conducted by the University of Rochester Cancer Center URCC in which patients with non-small cell lung cancer will be treated with radiation therapy and a drug called paclitaxel Paclitaxel is a natural product with anticancer properties The first purpose of this study is to determine the dose of paclitaxel which when given in combination with radiation therapy will provide the greatest effect have the least side effects To determine this patients will be put on the study in groups of 3 The dose for each additional group will be higher than the previous dose until the maximum tolerated dose is reached The second purpose is to determine if radiation therapy with paclitaxel is more effective in treating lung cancer than radiation therapy alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None